Published in AIDS Weekly, October 2nd, 1995
The patients who received stavudine had better immune function (higher CD4 counts), maintained higher weight, and lived slightly longer than those who remained on zidovudine. The drug was very well tolerated. This is the first study showing the clinical efficacy of stavudine, the newest drug licensed by the FDA for the treatment of HIV.
Stavudine was licensed in the summer of 1995...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.